← Russell 3000 cross-section

ILMN ILLUMINA, INC.

Trailing twelve months to 2026-06-28 · as filed 2026-07-31, not restated
Healthcare

Scale

Market cap
$34.7bn
Revenue TTM
$4.5bn
Net income TTM
$825m
Free cash flow
$931m
Composite score
56.2
Sector rank
#305

Valuation

P / E
42.0
EV / EBITDA
29.9
EV / sales
7.7
FCF yield
2.69%
Earnings yield vs 10-yr
-2.35pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
18.4%
EBITDA margin
25.7%
ROE
29.1%
ROIC
32.6%
Revenue growth
4.9%

Insider activity, last 90 days

Net open-market
$-487.09m
Buyers
0
Sellers
5

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Financial Overview In 2024, we outlined key strategic goals focused on a return to revenue growth and improved margin performance by the end of 2027. Revenue increased 7% to $2,251 million and operating margin increased to 20.2% in YTD 2026 as compared to 18.0% in YTD 2025. Moreover, in 2026, we have experienced higher fuel, energy, and shipping costs related to the conflict and instability in the Middle East and higher costs associated with memory chips used in our products, both of which have negatively impacted gross margin in 2026. …ILLUMINA, INC., 10-Q, period ended 2026-06-28, filed 2026-07-31

Read the full passage →